<div><div></div><div><span><p><strong><span>Soligenix increased the maximum amount of common stock available for sale under its at‑market sales agreement by $2,956,000.</span></strong></p><p><strong><span>Key Highlights:</span></strong></p><ul><li><span>Filed a prospectus supplement on May 28, 2026 to boost the Sales Agreement capacity by $2,956,000.</span></li><li><span>Previously sold approximately $3,445,000 of common stock under the same Sales Agreement.</span></li><li><span>Legal opinion regarding the $2,956,000 of shares is filed as Exhibit 5.1 with the filing.</span></li></ul><p><span>Original SEC Filing: </span>SOLIGENIX, INC. [ SNGX ] - 8-K - May. 28, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

SNGX

<p>Soligenix has increased the maximum amount of common stock available for sale under its at-market sales agreement by $2,956,000. A prospectus supplement was filed on May 28, 2026, to boost the sales capacity. Previously, approximately $3,445,000 of common stock was sold under the same agreement.</p>

Soligenix raises at‑market share capacity by $2.956M under sales agreement